Xvivo Perfusion AB (publ) (LON:0RKL)
London · Delayed Price · Currency is GBP · Price in SEK 175.68
+1.16 (0.67%)
At close: Oct 21, 2025
Xvivo Perfusion AB Revenue
Xvivo Perfusion AB had revenue of 189.14M SEK in the quarter ending September 30, 2025, a decrease of -4.71%. This brings the company's revenue in the last twelve months to 813.59M, up 8.39% year-over-year. In the year 2024, Xvivo Perfusion AB had annual revenue of 822.42M with 37.63% growth.
Revenue (ttm)
813.59M SEK
Revenue Growth
+8.39%
P/S Ratio
7.15
Revenue / Employee
4.28M SEK
Employees
190
Market Cap
459.15M GBP
Revenue Chart
* This company reports financials in SEK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 822.42M | 224.87M | 37.63% |
| Dec 31, 2023 | 597.54M | 182.25M | 43.88% |
| Dec 31, 2022 | 415.29M | 156.91M | 60.73% |
| Dec 31, 2021 | 258.39M | 78.53M | 43.66% |
| Dec 31, 2020 | 179.86M | -40.98M | -18.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 41.24B |
| GSK plc | 31.63B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Hikma Pharmaceuticals | 2.35B |
| ConvaTec Group | 1.72B |
| Spire Healthcare Group | 1.55B |
| Genus | 672.80M |
Xvivo Perfusion AB News
- 3 months ago - Xvivo Perfusion AB (XVIPF) Q2 2025 Earnings Call Highlights: Navigating Challenges and Seizing ... - GuruFocus
- 3 months ago - Q2 2025 Xvivo Perfusion AB Earnings Call Transcript - GuruFocus